These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 2291658)
1. Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo. van Ogtrop ML; Mattie H; Guiot HF; van Strijen E; Hazekamp-van Dokkum AM; van Furth R Antimicrob Agents Chemother; 1990 Oct; 34(10):1932-7. PubMed ID: 2291658 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo. Mattie H; Sekh BA; van Ogtrop ML; van Strijen E Antimicrob Agents Chemother; 1992 Nov; 36(11):2439-43. PubMed ID: 1489186 [TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. Mattie H; van Dokkum AM; Brus-Weijer L; Krul AM; van Strijen E J Infect Dis; 1990 Sep; 162(3):717-22. PubMed ID: 2143771 [TBL] [Abstract][Full Text] [Related]
4. [Third generation cephalosporins (cefoperazone, cefotaxime, ceftazidime and ceftriaxone) in the prevention and treatment of experimental plague in albino mice]. Ryzhko IV; Tsuraeva RI; Pasiukov VV; Samokhodkina ED; Shcherbaniuk AI Antibiot Khimioter; 1996 May; 41(5):35-8. PubMed ID: 9054316 [TBL] [Abstract][Full Text] [Related]
5. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. van Ogtrop ML; Guiot HF; Mattie H; van Furth R Antimicrob Agents Chemother; 1991 May; 35(5):976-82. PubMed ID: 1854180 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Kalman D; Barriere SL; Johnson BL Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo. van Ogtrop ML; Mattie H; Guiot HF; van Strijen E; Sekh BR; van Furth R Antimicrob Agents Chemother; 1991 Mar; 35(3):417-22. PubMed ID: 2039191 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous multiresponse optimization of an HPLC method to separate seven cephalosporins in plasma and amniotic fluid: application to validation and quantification of cefepime, cefixime and cefoperazone. Nemutlu E; Kir S; Katlan D; Beksaç MS Talanta; 2009 Nov; 80(1):117-26. PubMed ID: 19782200 [TBL] [Abstract][Full Text] [Related]
9. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289 [TBL] [Abstract][Full Text] [Related]
10. [Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae]. Tuchiluş C; Poiată A; Bădicuţ I; Teodor A; Luca V; Grigore L; Buiuc D Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):595-8. PubMed ID: 14756068 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. Bijie H; Kulpradist S; Manalaysay M; Soebandrio A J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. McKinnon PS; Paladino JA; Schentag JJ Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273 [TBL] [Abstract][Full Text] [Related]
13. In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. Wang H; Yu Y; Xie X; Wang C; Zhang Y; Yuan Y; Zhang X; Liu J; Wang P; Chen M J Infect Chemother; 2000 Jun; 6(2):81-5. PubMed ID: 11810540 [TBL] [Abstract][Full Text] [Related]
14. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Norrby SR Am J Med; 1985 Aug; 79(2A):56-61. PubMed ID: 3895919 [TBL] [Abstract][Full Text] [Related]
15. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals. Klesel N; Limbert M; Schrinner E; Seeger K; Seibert G; Winkler I Infection; 1984; 12(4):286-92. PubMed ID: 6092278 [TBL] [Abstract][Full Text] [Related]
17. Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile. Berger SA; Levy Y; Halevy A; Gorea A; Orda R World J Surg; 1988 Oct; 12(5):641-4. PubMed ID: 3072775 [No Abstract] [Full Text] [Related]
18. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
19. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182 [TBL] [Abstract][Full Text] [Related]
20. Cephalosporin Resistance in Wang M; Zu X; Zhao Z; Fu F; Bai X; Gong X; Zhao P; Gao W; Xue Y Microb Drug Resist; 2020 Oct; 26(10):1250-1259. PubMed ID: 32013730 [No Abstract] [Full Text] [Related] [Next] [New Search]